Triglyceride trouble from tumors
A team led by researchers at the University of South Floridahas found that cancer cells alterboth the amount and the type of lipid in dendritic cells, decreasing their ability to initiate immunity. The finding could explain the poor immune response seen in many cancer patients-a phenomenon that has confounded many efforts to develop vaccines against tumor antigens.
Because dendritic cells (DCs) collect antigens and present them to T helper cells, they already are the targets of cancer vaccines and adjuvants. For example, Dendreon Corp.'s Provenge sipuleucel-T, the first cancer vaccine therapy approved in the U.S., is created by delivering